Department of Paediatrics, The Medical University of Warsaw, 01-184 Warsaw, Dzialdowska 1, Poland.
World J Gastroenterol. 2010 Jan 7;16(1):69-75. doi: 10.3748/wjg.v16.i1.69.
To systematically evaluate and update evidence on the efficacy and safety of probiotic supplementation for the treatment of constipation.
The MEDLINE, EMBASE, CINAHL, and Cochrane Library databases were searched in May 2009 for randomised controlled trials (RCTs) performed in paediatric or adult populations related to the study aim.
We included five RCTs with a total of 377 subjects (194 in the experimental group and 183 in the control group). The participants were adults (three RCTs, n = 266) and children (two RCTs, n = 111) with constipation. In adults, data suggests a favourable effect of treatment with Bifidobacterium lactis DN-173 010, Lactobacillus casei Shirota, and Escherichia coli Nissle 1917 on defecation frequency and stool consistency. In children, L. casei rhamnosus Lcr35, but not L. rhamnosus GG, showed a beneficial effect.
Until more data are available, we believe the use of probiotics for the treatment of constipation condition should be considered investigational.
系统评价和更新益生菌补充剂治疗便秘的疗效和安全性证据。
检索 2009 年 5 月 MEDLINE、EMBASE、CINAHL 和 Cochrane 图书馆数据库，以获取与研究目的相关的儿科或成人人群的随机对照试验（RCT）。
我们纳入了 5 项 RCT，共有 377 名受试者（实验组 194 名，对照组 183 名）。参与者为成年人（3 项 RCT，n = 266）和儿童（2 项 RCT，n = 111），患有便秘。在成年人中，双歧杆菌 lactis DN-173 010、干酪乳杆菌 Shirota 和大肠杆菌 Nissle 1917 的治疗数据表明对排便频率和粪便稠度有有利影响。在儿童中，鼠李糖乳杆菌 Lcr35 但不是鼠李糖乳杆菌 GG 显示出有益的效果。
在更多数据可用之前，我们认为使用益生菌治疗便秘应被视为研究性的。
